Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions
- PMID: 10229196
- DOI: 10.1038/sj.onc.1202565
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions
Abstract
Inheritance of germ-line mutant alleles of BRCA1 and BRCA2 confers a markedly increased risk of breast cancer and we have previously reported a higher incidence of p53 mutations in these tumours than in grade matched sporadic tumours. We have now characterized these p53 mutants. The results of these studies identify a novel class of p53 mutants previously undescribed in human cancer yet with multiple occurrences in BRCA-associated tumours which retain a profile of p53-dependent activities in terms of transactivation, growth suppression and apoptosis induction which is close or equal to wild-type. However, these mutants fail to suppress transformation and exhibit gain of function transforming activity in rat embryo fibroblasts. These mutants therefore fall into a novel category of p53 mutants which dissociate transformation suppression from other wild-type functions. The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.
Similar articles
-
p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.Oncogene. 1998 Oct 1;17(13):1681-9. doi: 10.1038/sj.onc.1202106. Oncogene. 1998. PMID: 9796697
-
TP53 mutations in familial breast cancer: functional aspects.Hum Mutat. 2003 Mar;21(3):301-6. doi: 10.1002/humu.10173. Hum Mutat. 2003. PMID: 12619116 Review.
-
p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.Oncogene. 2001 Jun 14;20(27):3573-9. doi: 10.1038/sj.onc.1204468. Oncogene. 2001. PMID: 11429705
-
The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras.Oncogene. 1996 Sep 5;13(5):995-1007. Oncogene. 1996. PMID: 8806689
-
[Progress in molecular genetics of correlating genes of breast cancer].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Apr;19(2):152-5. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002. PMID: 11941595 Review. Chinese.
Cited by
-
Recurrent TP53 missense mutation in cancer patients of Arab descent.Fam Cancer. 2017 Apr;16(2):295-301. doi: 10.1007/s10689-016-9951-z. Fam Cancer. 2017. PMID: 27866339
-
Killing the umpire: cooperative defects in mitotic checkpoint and BRCA2 genes on the road to transformation.Breast Cancer Res. 1999;1(1):8-10. doi: 10.1186/bcr4. Epub 1999 Oct 7. Breast Cancer Res. 1999. PMID: 11250674 Free PMC article.
-
p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes.Mol Cell Biol. 2000 May;20(10):3705-14. doi: 10.1128/MCB.20.10.3705-3714.2000. Mol Cell Biol. 2000. PMID: 10779360 Free PMC article.
-
BRCA1-Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression.Cancers (Basel). 2018 Dec 14;10(12):513. doi: 10.3390/cancers10120513. Cancers (Basel). 2018. PMID: 30558184 Free PMC article. Review.
-
Mutant p53 in cancer: new functions and therapeutic opportunities.Cancer Cell. 2014 Mar 17;25(3):304-17. doi: 10.1016/j.ccr.2014.01.021. Cancer Cell. 2014. PMID: 24651012 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous